Cargando…

Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)—A Single Center, Retrospective Observational Study

Precision oncology and immunotherapy have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Emerging studies show that targeted therapies are also beneficial for patients with driver alterations such as epidermal growth factor receptor (EGFR) mutations in early-stage NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stephan-Falkenau, Susann, Streubel, Anna, Mairinger, Thomas, Kollmeier, Jens, Misch, Daniel, Thiel, Sebastian, Bauer, Torsten, Pfannschmidt, Joachim, Hollmann, Manuel, Wessolly, Michael, Blum, Torsten Gerriet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604339/ https://www.ncbi.nlm.nih.gov/pubmed/36293366 http://dx.doi.org/10.3390/ijms232012511

Ejemplares similares

Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies
por: Stephan-Falkenau, Susann, et al.
Publicado: (2023)

Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing
por: Streubel, Anna, et al.
Publicado: (2019)

Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy
por: Wessolly, Michael, et al.
Publicado: (2022)

The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
por: Boch, Christian, et al.
Publicado: (2013)

Autoimmune disorders and paraneoplastic syndromes in thymoma
por: Blum, Torsten Gerriet, et al.
Publicado: (2020)

A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient’s Suitability for Immune Checkpoint Inhibition
por: Wessolly, Michael, et al.
Publicado: (2020)

Morphometrical analysis of transbronchial cryobiopsies
por: Griff, Sergej, et al.
Publicado: (2011)

Erratum to: Morphometrical analysis of transbronchial cryobiopsies
por: Griff, Sergej, et al.
Publicado: (2016)

Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer
por: Misch, Daniel, et al.
Publicado: (2015)

Diagnostic yield of transbronchial cryobiopsy in non-neoplastic lung disease: a retrospective case series
por: Griff, Sergej, et al.
Publicado: (2014)

Narrow band imaging (NBI) during medical thoracoscopy: first impressions
por: Schönfeld, Nicolas, et al.
Publicado: (2009)

Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors
por: Wessolly, Michael, et al.
Publicado: (2018)

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
por: Hager, Thomas, et al.
Publicado: (2023)

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
por: Xanthopoulos, Athanasios, et al.
Publicado: (2008)

Determinants of plasma calretinin in patients with malignant pleural mesothelioma
por: Lehnert, Martin, et al.
Publicado: (2020)

Highlights of thoracic oncology from the 2018 ERS International Congress
por: Ntontsi, Polyxeni, et al.
Publicado: (2019)

ERS International Congress, Madrid, 2019: highlights from the Thoracic Oncology Assembly
por: Costantini, Adrien, et al.
Publicado: (2020)

KRAS(G12C)/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma
por: Frost, Nikolaj, et al.
Publicado: (2021)

Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model
por: Borchert, Sabrina, et al.
Publicado: (2023)

New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey
por: Berghmans, Thierry, et al.
Publicado: (2018)

Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study
por: Mathilakathu, Alexander, et al.
Publicado: (2021)

A Patient with Non-Hodgkin Lymphoma and Nonspecific Interstitial Pneumonia during Ibrutinib Therapy
por: Jungmann, Sven, et al.
Publicado: (2017)

Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity
por: Brcic, Luka, et al.
Publicado: (2021)

Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy
por: Mairinger, Fabian D., et al.
Publicado: (2018)

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
por: Borchert, Sabrina, et al.
Publicado: (2019)

Value of (18)F FDG-PET/CT parameters on long term follow-up for patients with non-small cell lung cancer
por: Zoair, Mohammed, et al.
Publicado: (2022)

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
por: Walter, Robert F. H., et al.
Publicado: (2018)

Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma
por: Zhao, Jemmy, et al.
Publicado: (2023)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy
por: Pisapia, Pasquale, et al.
Publicado: (2022)

Fibroblast activation protein-α expression in fibroblasts is common in the tumor microenvironment of colorectal cancer and may serve as a therapeutic target
por: Greimelmaier, K., et al.
Publicado: (2023)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Diffuse Alveolar Hemorrhage Associated with Epithelioid Angiosarcoma of the Lung: A Challenging Diagnosis
por: Wuest, Felix, et al.
Publicado: (2023)

Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer
por: Wessolly, Michael, et al.
Publicado: (2022)

CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer
por: Wessolly, Michael, et al.
Publicado: (2022)

PD-L1 Dependent Immunogenic Landscape in Hot Lung Adenocarcinomas Identified by Transcriptome Analysis
por: Kirfel, Jutta, et al.
Publicado: (2021)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
por: Weber, Daniel G., et al.
Publicado: (2014)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
por: Mairinger, Fabian Dominik, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eep2u010vbs30l4h8h79la8uop